AstraZeneca (AZN)
Camizestrant combination delayed time to first progression in patients with advanced HR-positive breast cancer with an ESR1 tumour mutation
Camizestrant combination delayed time to first progression in patients with advanced HR-positive breast cancer with an ESR1 tumour mutation
📉 **NEGATIVE** • Medium confidence analysis (73%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (5%) **Content type:** Clinical